USPSTF: Docs should talk with high-risk women about breast cancer drugs

09/24/2013 | Reuters

The U.S. Preventive Services Task Force has released a statement recommending that physicians talk with women at high risk of developing breast cancer about drugs that might reduce their risk. Tamoxifen or raloxifene interfere with the effects of estrogen in breast tissue, but they are associated with side effects including blood clot risk.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Director of Litigation
Center for Science in the Public Interest
Washington, DC
Health Plan CEO - Oregon
Trillium Community Health Plan
Eugene, OR
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC